Xoma Royalty Corporation (XOMA)

$26.59 +0.41 (1.57%)
Market Cap 312.67M
Revenue (ttm) 28.49M
Net Income (ttm) -13.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 86.87
Profit Margin -48.51%
Debt to Equity Ratio 1.01
Volume 834,859
Avg Vol 85,738
Day's Range N/A - N/A
Shares Out 12.38M
Stochastic %K 60%
Beta 0.94
Analysts Strong Sell
Price Target $64.50

Company Profile

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 204 7200
Address:
2200 Powell Street, Suite 310, EmeryVille, United States
notreload_ai
notreload_ai Dec. 16 at 11:44 AM
Wells Fargo upgrades $GLUE on 2026 catalysts, while Jefferies downgrades $GBIO due to its pending acquisition by $XOMA https://notreload.xyz/wells-fargo-upgrades-glue-jefferies-downgrades-gbio/
0 · Reply
TwongStocks
TwongStocks Dec. 15 at 10:01 PM
$XOMA Enters into Agreement to Acquire $GBIO https://www.globenewswire.com/news-release/2025/12/15/3205887/0/en/XOMA-Royalty-Enters-into-Agreement-to-Acquire-Generation-Bio.html • $4.2913 per share at the closing of the merger, plus 1 CVR
0 · Reply
murphylaw
murphylaw Dec. 13 at 4:42 PM
$XOMA what a deal. Low risk high reward stock. Hoping i could get in at low 30s. This is a gift!
0 · Reply
RunnerSignals
RunnerSignals Dec. 12 at 8:42 PM
Stock Upgrades Today Show Top Picks $GCTS $IBRX $XOMA $BBOT $VG Ultra-high-octane crew today. Feels like the market found a hidden cheat code for upside https://stocksrunner.com/news/2025-12-12-stock-upgrades-today-show-top-picks
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 12 at 1:13 AM
$XOMA Share Price: $26.52 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.76 – $3.38 Potential Upside: 66% ROI Time to Expiration: 188 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Jon752
Jon752 Dec. 11 at 8:30 PM
$XOMA Royalty Portfolio – XOMA Royalty https://share.google/1BK4pt5zhhg6J6304
0 · Reply
Wisenheimer
Wisenheimer Dec. 11 at 7:59 PM
$XOMA we will see new lows - their other projects wont be enough to move the needle even if approved. Rest of stuff is ph1-2
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 6:53 PM
HC Wainwright & Co. has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 97.
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 11 at 6:10 PM
$XOMA could hit 21$ wait
0 · Reply
medguy
medguy Dec. 11 at 5:58 PM
Looking fot bounce $ORCL $PSNY $FBYD $XOMA $OXM
0 · Reply
Latest News on XOMA
XOMA Royalty Declares Quarterly Preferred Stock Dividends

Dec 22, 2025, 7:30 AM EST - 9 days ago

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Dec 5, 2025, 9:00 AM EST - 26 days ago

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Mural Oncology Announces Sanction of the Scheme by the High Court

Dec 3, 2025, 4:30 PM EST - 4 weeks ago

Mural Oncology Announces Sanction of the Scheme by the High Court

MURA

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

Nov 21, 2025, 7:45 AM EST - 5 weeks ago

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Nov 12, 2025, 7:30 AM EST - 7 weeks ago

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

Oct 17, 2025, 11:45 AM EDT - 2 months ago

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

XOMA Royalty PFD Update: Going Back To My Original Sell Ratings

Oct 3, 2025, 8:00 AM EDT - 3 months ago

XOMA Royalty PFD Update: Going Back To My Original Sell Ratings

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

Oct 2, 2025, 4:43 PM EDT - 3 months ago

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

Sep 24, 2025, 6:00 AM EDT - 3 months ago

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

EPIX

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

Sep 17, 2025, 9:00 AM EDT - 3 months ago

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 4 months ago

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

Aug 20, 2025, 8:49 AM EDT - 4 months ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Aug 13, 2025, 7:30 AM EDT - 5 months ago

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

Aug 5, 2025, 9:20 PM EDT - 5 months ago

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

Aug 5, 2025, 6:01 PM EDT - 5 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

HLVX

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

Aug 4, 2025, 7:30 AM EDT - 5 months ago

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

Jul 14, 2025, 8:00 AM EDT - 6 months ago

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

EPIX

Collect Up To 11.5% From The Healthcare Sector

Jul 6, 2025, 10:15 AM EDT - 6 months ago

Collect Up To 11.5% From The Healthcare Sector

THQ

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Jun 27, 2025, 7:30 AM EDT - 6 months ago

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025, 8:01 AM EDT - 7 months ago

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025, 7:30 AM EDT - 8 months ago

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Apr 14, 2025, 7:30 AM EDT - 9 months ago

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

Apr 8, 2025, 7:15 AM EDT - 9 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

TAK

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

Apr 8, 2025, 12:24 AM EDT - 9 months ago

XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

Apr 2, 2025, 7:30 AM EDT - 9 months ago

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Mar 17, 2025, 4:30 PM EDT - 10 months ago

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 11 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

XOMA Royalty to Present at Investor Conferences in March

Feb 24, 2025, 4:05 PM EST - 11 months ago

XOMA Royalty to Present at Investor Conferences in March

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 11 months ago

XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Nov 7, 2024, 7:30 AM EST - 1 year ago

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Oct 22, 2024, 8:00 AM EDT - 1 year ago

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

TWST

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

Oct 15, 2024, 10:31 AM EDT - 1 year ago

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 1 year ago

I Am Banking On The Silver Tsunami With Big Dividends

HROW THQ

XOMA Stock Dips Amidst Biotech Sector Decline

Oct 3, 2024, 3:53 PM EDT - 1 year ago

XOMA Stock Dips Amidst Biotech Sector Decline

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

Sep 23, 2024, 6:30 AM EDT - 1 year ago

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty to Present at Upcoming Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty to Present at Upcoming Investor Conferences in September

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Aug 13, 2024, 7:30 AM EDT - 1 year ago

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

My 2 Top Royalty Income Picks, Yields Up To 9.5%

Jul 19, 2024, 8:30 AM EDT - 1 year ago

My 2 Top Royalty Income Picks, Yields Up To 9.5%

KRP

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29, 2024, 2:31 AM EDT - 1 year ago

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

XOMA Declares Quarterly Preferred Stock Dividends

Jun 20, 2024, 7:30 AM EDT - 1 year ago

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

Jun 12, 2024, 7:30 AM EDT - 1 year ago

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

Jun 3, 2024, 7:45 PM EDT - 1 year ago

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

May 14, 2024, 7:30 AM EDT - 1 year ago

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

May 9, 2024, 7:30 AM EDT - 1 year ago

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Apr 25, 2024, 7:30 AM EDT - 1 year ago

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB PGEN

XOMA Corporation Announces Closing of Tender Offer

Apr 3, 2024, 9:00 AM EDT - 1 year ago

XOMA Corporation Announces Closing of Tender Offer

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Mar 19, 2024, 4:05 PM EDT - 1 year ago

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Mar 13, 2024, 11:49 AM EDT - 1 year ago

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

notreload_ai
notreload_ai Dec. 16 at 11:44 AM
Wells Fargo upgrades $GLUE on 2026 catalysts, while Jefferies downgrades $GBIO due to its pending acquisition by $XOMA https://notreload.xyz/wells-fargo-upgrades-glue-jefferies-downgrades-gbio/
0 · Reply
TwongStocks
TwongStocks Dec. 15 at 10:01 PM
$XOMA Enters into Agreement to Acquire $GBIO https://www.globenewswire.com/news-release/2025/12/15/3205887/0/en/XOMA-Royalty-Enters-into-Agreement-to-Acquire-Generation-Bio.html • $4.2913 per share at the closing of the merger, plus 1 CVR
0 · Reply
murphylaw
murphylaw Dec. 13 at 4:42 PM
$XOMA what a deal. Low risk high reward stock. Hoping i could get in at low 30s. This is a gift!
0 · Reply
RunnerSignals
RunnerSignals Dec. 12 at 8:42 PM
Stock Upgrades Today Show Top Picks $GCTS $IBRX $XOMA $BBOT $VG Ultra-high-octane crew today. Feels like the market found a hidden cheat code for upside https://stocksrunner.com/news/2025-12-12-stock-upgrades-today-show-top-picks
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 12 at 1:13 AM
$XOMA Share Price: $26.52 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.76 – $3.38 Potential Upside: 66% ROI Time to Expiration: 188 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Jon752
Jon752 Dec. 11 at 8:30 PM
$XOMA Royalty Portfolio – XOMA Royalty https://share.google/1BK4pt5zhhg6J6304
0 · Reply
Wisenheimer
Wisenheimer Dec. 11 at 7:59 PM
$XOMA we will see new lows - their other projects wont be enough to move the needle even if approved. Rest of stuff is ph1-2
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 6:53 PM
HC Wainwright & Co. has updated their rating for XOMA Royalty ( $XOMA ) to Buy with a price target of 97.
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 11 at 6:10 PM
$XOMA could hit 21$ wait
0 · Reply
medguy
medguy Dec. 11 at 5:58 PM
Looking fot bounce $ORCL $PSNY $FBYD $XOMA $OXM
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 5:38 PM
Leerink Partners updates rating for XOMA Royalty ( $XOMA ) to Outperform, target set at 58 → 45.
0 · Reply
Jon752
Jon752 Dec. 11 at 4:32 PM
$XOMA https://www.investors.com/news/technology/xoma-stock-rezolute-stock-hyperinsulinism-treatment/?src=A00220
0 · Reply
Jon752
Jon752 Dec. 11 at 1:40 PM
$XOMA 3 shares brings it down $7.50
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 5:11 PM
LUCID CAPITAL MARKETS updates rating for XOMA Royalty ( $XOMA ) to Buy, target set at 76.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 8 at 11:35 PM
$XOMA CEO purchased 100,000 shares at $25.05 for a total of $2,505,000. Hughes Owen now owns 200,563 shares. https://ceo-buys.com
0 · Reply
TwongStocks
TwongStocks Nov. 21 at 1:00 PM
$XOMA completes acquisition of $LVTX https://www.globenewswire.com/news-release/2025/11/21/3192735/7281/en/XOMA-Royalty-Announces-Closing-of-Transactions-to-Acquire-LAVA-Therapeutics-N-V.html
0 · Reply
Mergerbrief
Mergerbrief Nov. 20 at 11:53 AM
$LVTX / $XOMA – Subsequent Offer Period Expires MergerBrief.com For Full Schedule
0 · Reply
TwongStocks
TwongStocks Nov. 13 at 10:18 PM
$LVTX NASDAQ Equity Corporate Actions Alert # 2025 - 611 Information Regarding the Tender Offer of LAVA Therapeutics N.V. (LVTX) https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2025-611 The initial tender offer by $XOMA to acquire all of the outstanding common stock of $LVTX expired one minute after 11:59 p.m. ET, November 12, 2025. A subsequent offering is scheduled to expire one minute after 11:59 p.m. ET, November 20, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on November 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on November 20, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (November 21st) and will be suspended effective November 24, 2025. At closing, LVTX shareholders will receive $1.04 and 1 CVR for each share held.
0 · Reply
d_risk
d_risk Nov. 12 at 4:18 PM
$XOMA - XOMA Royalty Corporation Common Stock - 10Q - Updated Risk Factors XOMA flags new risks: market volatility or economic downturns (including tariffs) could hit results and liquidity, and FDA or government agency disruptions may delay partner regulatory reviews, impacting business. #Biotechnology #GovernmentDisruptions #EconomicDownturn #RegulatoryRisk #MarketVolatility 🟢 Added 🟠 Removed https://d-risk.ai/XOMA/10-Q/2025-11-12
0 · Reply
lecorb
lecorb Nov. 12 at 12:52 PM
$XOMA XOMA GAAP EPS of $0.70 beats by $0.74, revenue of $9.35M misses by $2.12M
0 · Reply
Mergerbrief
Mergerbrief Oct. 24 at 11:56 AM
$MURA / $XOMA - Shareholder Vote $MURA MergerBrief.com For Full Schedule
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 17 at 6:45 PM
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-amended-deal-with-xoma-royalty/ch6sjlqR3o3
0 · Reply